OS Therapies Inc.
09/30/2025 | Press release | Distributed by Public on 09/30/2025 14:07
Material Event (Form 8-K)
Item 8.01. Other Events.
On September 30, 2025, OS Therapies Incorporated (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), which forms a part of the Company's registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 12, 2025. The Prospectus Supplement covers the resale from time to time of up to 4,373,043 shares of the Company's common stock (the "Shares") by the selling stockholders referenced in the Prospectus Supplement. The Company is filing this Current Report on Form 8-K to provide the legal opinion of its counsel, Olshan Frome Wolosky LLP, regarding the legality of Shares, which is attached hereto as Exhibit 5.1.
OS Therapies Inc. published this content on September 30, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 30, 2025 at 20:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]